花旗发表报告指，药明康德管理层上调2025年指引，主要是由于产能快速扩张，而非关税战前的订单激增。管理层预期2025年下半年持续经营业务收入将实现按年及较上半年双位数增长，全年新指引意味按年增长5%至10%、较上半年增长6%至11%。花旗未大幅上调药明康德收入预测，因在一季度业绩公布后已调升预期。基于化学业务推动的毛利率扩张、行政管理费用率下降，以及更高的投资收益，该行将药明康德2025年至2027年每股盈利预测分别上调3%、6%及7%。因此，鉴于更乐观的盈利前景，该行将H股目标价从95港元上调至130港元，A股目标价从88元上调至119元，列为合同研发生产组织(CDMO)领域的首选股，评级“买入”。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.